The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Abstract Details
|
Activity Number:
|
193
|
|
Type:
|
Roundtables
|
|
Date/Time:
|
Monday, August 1, 2011 : 12:30 PM to 1:50 PM
|
|
Sponsor:
|
ENAR
|
| Abstract - #303445 |
|
Title:
|
Methodology to Assess Surrogate Markers in Clinical Trials
|
|
Author(s):
|
Jeremy Michael George Taylor*+
|
|
Companies:
|
University of Michigan
|
|
Address:
|
Dept of Biostatistics, Ann Arbor, MI, 48109,
|
|
Keywords:
|
|
|
Abstract:
|
There is a strong desire to use surrogate endpoints in randomized clinical trials, instead of true clinical endpoints. Using surrogate endpoints could shorten the duration of the trials and reduce their cost, enabling more therapies to be evaluated. There are significant statistical challenges in demonstrating that a potential surrogate endpoint is valid. A number of statistical approaches have been suggested, including metrics for the proportion of treatment effect explained, within and between trial measures of association between the surrogate and the true endpoint, and counterfactual models.
|
The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.
Back to the full JSM 2011 program
|
2011 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.